Title(s):
Associate Professor of Oncology
Associate Professor of Pediatrics
Associate Professor of Pediatrics
Director, Fellowship Training Pediatric Hematology/Oncology
Associate Professor
Director, Pediatric Neuro-Oncology
Clinical Director Pediatric Oncology
Associate Professor
Director, Pediatric Neuro-Oncology
Clinical Director Pediatric Oncology
Appointment Phone:
410-955-8964
Primary Location:
The Johns Hopkins Hospital
Expertise:
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Aplastic Anemia, General Pediatrics, Hematologic Malignancies, Hodgkin's Disease, Leukemia, Leukemia/Lymphoma, Non-Hodgkin's Lymphoma, Pediatric Brain Cancer, Pediatric Brain Tumors, Pediatric Lymphomas, Pediatric Neuro-Oncology, Pediatric Oncology, Pediatric Spinal Cord Tumors
Education and Experience
Training
- SUNY Upstate Medical University (Syracuse NY)/ (1987)
Certifications
- Pediatric Hematology/Oncology, American Board of Pediatrics (2009)
Locations
The Johns Hopkins Hospital
600 N. Wolfe Street
Hospital Main Entrance - Sheikh Zayed Tower
Baltimore, MD 21287
Appointment Phone: 410-955-8964
Fax: 410-955-0028
Location Map
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
401 N. Broadway
Baltimore, MD 21231
Appointment Phone: 410-955-8964
Fax: 410-955-0028
Location Map
Department / Division
- Oncology
Centers/Institutes
Centers / Institutes
- Johns Hopkins Children's Center
- Sidney Kimmel Comprehensive Cancer Center
Bio
Biography
Dr. Cohen is the Director of Pediatric Neuro-Oncology and the Clinical Director in the Division of Pediatric Oncology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. He received his undergraduate degree at Brown University, completed medical school at the Upstate Medical University in Syracuse, NY. He did his general Pediatric Residency and Chief Residency at the University of Colorado. He completed his Pediatric Hematology/Oncology Fellowship at Johns Hopkins and has been a member of the faculty since 1994. Dr. Cohen is the co-chair of the High-Grade Glioma committee for the Childrens Oncology Group and in that capacity has a particular research interest in the development of therapeutics for the treatment of infiltrating gliomas. He is the Chief Medical Officer and head of the Scientific Advisory Board for Solving Kids Cancer. He is a Scientific Advisor for the Childhood Brain Tumor Foundation.
The Pediatric Neuro-Oncology program provides a wide-range of research. Clinically, a major focus of the program is the development and testing of novel therapeutics for children with brain tumors. Included in this research has been the use of low-dose, long exposure treatment strategies as well as the selective use of high-dose regimens in the treatment of these children. Recognizing the multidisciplinary nature of this work, there is constant collaboration with specialists in pediatric neurosurgery, radiation oncology, neuropathology, neuroradiology, neurology, neuro-ophthalmology and other supporting disciplines. Research is also coordinated with the Neuropsychology group at the Kennedy-Krieger Institute.
The Pediatric Neuro-Oncology program provides a wide-range of research. Clinically, a major focus of the program is the development and testing of novel therapeutics for children with brain tumors. Included in this research has been the use of low-dose, long exposure treatment strategies as well as the selective use of high-dose regimens in the treatment of these children. Recognizing the multidisciplinary nature of this work, there is constant collaboration with specialists in pediatric neurosurgery, radiation oncology, neuropathology, neuroradiology, neurology, neuro-ophthalmology and other supporting disciplines. Research is also coordinated with the Neuropsychology group at the Kennedy-Krieger Institute.
Physician Title
Director, Fellowship Training Pediatric Hematology/Oncology
Associate Professor
Director, Pediatric Neuro-Oncology
Clinical Director Pediatric Oncology
Associate Professor
Director, Pediatric Neuro-Oncology
Clinical Director Pediatric Oncology
Awards and Honors
Chief Medical Officer, Solving Kids Cancer Scientific Advisory Board
Expertise
- Acute Lymphoblastic Leukemia
- Acute Myeloid Leukemia
- Aplastic Anemia
- General Pediatrics
- Hematologic Malignancies
- Hodgkin's Disease
- Leukemia
- Leukemia/Lymphoma
- Non-Hodgkin's Lymphoma
- Pediatric Brain Cancer
- Pediatric Brain Tumors
- Pediatric Lymphomas
- Pediatric Neuro-Oncology
- Pediatric Oncology
- Pediatric Spinal Cord Tumors
Research
Research and Publications
Journal Citations
Chi SN, Zimmerman MA, Yao X, Fletcher W, Cohen KJ, Burger PC et. al. Intensive Multi-Modality Treatment for Children with Newly Diagnosed Central Nervous System Atypical Teratoid Rhabdoid Tumor. J of Clin Onc, 2009 Jan 20;27(3):385-9.
Frazier JL, Lee J, Thomale UW, Noggle JC, Cohen KJ, Jallo GI. Treatment of diffuse intrinsic brainstem gliomas: failed approaches and future strategies. J Neurosurg Pediatr. 2009 Apr;3(4): 259-89
Cohen KJ. Challenges in the management of pediatric malignant gliomas. Neuro-Oncology, 2009 Dec, SP-15.
Massimino M, Cohen KJ, Finlay JL.Is there a role for myeloablative chemotherapy with autologous hematopoietic cell rescue in the management of childhood high-grade astrocytomas? Pediatr Blood Cancer. 2010 Apr;54(4):641-3.
Pollack IF, Hamilton RL, Sobol RW, Nikiforova MN, Nikiforov YE, Lyons-Weiler MA, Laframboise WA, Burger PC, Brat DJ, Rosenblum MK, Gilles FH, Yates AJ, Zhou T, Cohen KJ, Finlay JL, Jakacki RI; for the Children's Oncology Group. Mismatch repair deficiency is an uncommon mechanism of alkylator resistance in pediatric malignant gliomas: A report from the children's oncology group. Pediatr Blood Cancer. 2010 Jun 29. [Epub ahead of print]
Hales RK, Shokek O, Burger PC, Paynter NP, Chaichana KL, Quiones-Hinojosa A, Jallo GI, Cohen KJ, Song DY, Carson BS, Wharam MD. Prognostic factors in pediatric high-grade astrocytoma: the importance of accurate pathologic diagnosis. J Neurooncol. 2010 Aug;99(1):65-71
Horsk A, Laclair A, Mohamed M, Wells CT, McNutt T, Cohen KJ, Wharam M, Mahone EM, Kates W. Low cerebellar vermis volumes and impaired neuropsychologic performance in children treated for brain tumors and leukemia.AJNR Am J Neuroradiol. 2010 Sep;31(8):1430-7.
Pollack IF, Hamilton RL, Burger PC, Brat DJ, Rosenblum MK, Murdoch GH, Nikiforova MN, Holmes EJ, Zhou T, Cohen KJ, Jakacki RI; Children's Oncology Group.Akt activation is a common event in pediatric malignant gliomas and a potential adverse prognostic marker: a report from the Children's Oncology Group.J Neurooncol. 2010 Sep;99(2):155-63.
Cohen KJ, Pollack IF, Zhou T, Buxton A, Holmes EJ, Burger PC, Brat DJ, Rosenblum MK, Hamilton RL, Lavey RS, Heideman RL. Temozolomide in the treatment of high-grade gliomas in children; a report from the Childrens Oncology Group. Neuro-Oncology, in press.
Chi SN, Zimmerman MA, Yao X, Fletcher W, Cohen KJ, Burger PC et. al. Intensive Multi-Modality Treatment for Children with Newly Diagnosed Central Nervous System Atypical Teratoid Rhabdoid Tumor. J of Clin Onc, 2009 Jan 20;27(3):385-9.
Frazier JL, Lee J, Thomale UW, Noggle JC, Cohen KJ, Jallo GI. Treatment of diffuse intrinsic brainstem gliomas: failed approaches and future strategies. J Neurosurg Pediatr. 2009 Apr;3(4): 259-89
Cohen KJ. Challenges in the management of pediatric malignant gliomas. Neuro-Oncology, 2009 Dec, SP-15.
Massimino M, Cohen KJ, Finlay JL.Is there a role for myeloablative chemotherapy with autologous hematopoietic cell rescue in the management of childhood high-grade astrocytomas? Pediatr Blood Cancer. 2010 Apr;54(4):641-3.
Pollack IF, Hamilton RL, Sobol RW, Nikiforova MN, Nikiforov YE, Lyons-Weiler MA, Laframboise WA, Burger PC, Brat DJ, Rosenblum MK, Gilles FH, Yates AJ, Zhou T, Cohen KJ, Finlay JL, Jakacki RI; for the Children's Oncology Group. Mismatch repair deficiency is an uncommon mechanism of alkylator resistance in pediatric malignant gliomas: A report from the children's oncology group. Pediatr Blood Cancer. 2010 Jun 29. [Epub ahead of print]
Hales RK, Shokek O, Burger PC, Paynter NP, Chaichana KL, Quiones-Hinojosa A, Jallo GI, Cohen KJ, Song DY, Carson BS, Wharam MD. Prognostic factors in pediatric high-grade astrocytoma: the importance of accurate pathologic diagnosis. J Neurooncol. 2010 Aug;99(1):65-71
Horsk A, Laclair A, Mohamed M, Wells CT, McNutt T, Cohen KJ, Wharam M, Mahone EM, Kates W. Low cerebellar vermis volumes and impaired neuropsychologic performance in children treated for brain tumors and leukemia.AJNR Am J Neuroradiol. 2010 Sep;31(8):1430-7.
Pollack IF, Hamilton RL, Burger PC, Brat DJ, Rosenblum MK, Murdoch GH, Nikiforova MN, Holmes EJ, Zhou T, Cohen KJ, Jakacki RI; Children's Oncology Group.Akt activation is a common event in pediatric malignant gliomas and a potential adverse prognostic marker: a report from the Children's Oncology Group.J Neurooncol. 2010 Sep;99(2):155-63.
Cohen KJ, Pollack IF, Zhou T, Buxton A, Holmes EJ, Burger PC, Brat DJ, Rosenblum MK, Hamilton RL, Lavey RS, Heideman RL. Temozolomide in the treatment of high-grade gliomas in children; a report from the Childrens Oncology Group. Neuro-Oncology, in press.
Research Interests
- More children die of brain tumors than any other form of pediatric cancer. Significant advances have been made in surgical and supportive care, but with less evident benefits in therapy. A variety of novel therapeutic agents and approaches are being studied in the hope of finding new approaches to treatment that are efficacious and ideally less toxic to the developing brain. The development of novel therapeutics is being driven by a growing translational initiative in cooperation with the neuropathology and neurosurgical sciences group.
More Info
Languages
- English
Memberships
ASPH/O, ASCO, SNO
Clinical Trials
- Pediatric brain tumors, medulloblastoma Pediatric Lymphomas and Neuro-Oncology
Additional Resources
Facebook
Twitter
Sharecare
Blogs
YouTube
RSS
Podcasts